Skip to main content

Advertisement

SpringerLink
Log in

Updates in heart failure 30-day readmission prevention

  • Published:
Heart Failure Reviews Aims and scope Submit manuscript

Abstract

Heart failure (HF) and HF 30-day readmission rates have been a major focus of efforts to reduce health care cost in the recent era. Since the implementation of the Affordable Care Act (ACA) in 2012 and the Hospital Readmission Reduction Program (HRRP), concerted efforts have focused on reduction of 30-day HF readmissions and other admission diagnoses targeted by the HRRP. Hospitals and organizations have instituted wide-ranging programs to reduce short-term readmissions, but the data supporting these programs is often mixed. In this review, we will discuss the challenges associated with reducing HF readmissions and summarize the rationale and effect of specific programs on HF 30-day readmission rates, ranging from medical therapy and adherence to remote hemodynamic monitoring. Finally, we will review the effect that the focus on reducing 30-day HF readmissions has had on the care of the HF patient.

This is a preview of subscription content, log in via an institution to check access.

Access this article

Log in via an institution

Price excludes VAT (USA)
Tax calculation will be finalised during checkout.

Instant access to the full article PDF.

Institutional subscriptions

Fig. 1

Similar content being viewed by others

References

  1. Readmissions-Reduction-Program (2018) https://www.cms.gov/medicare/medicare-fee-for-service-payment/acuteinpatientpps/readmissions-reduction-program.html. Accessed 16 April 2018

  2. Dharmarajan K, Wang Y, Lin Z, Normand SLT, Ross JS, Horwitz LI, Desai NR, Suter LG, Drye EE, Bernheim SM, Krumholz HM (2017) Association of changing hospital readmission rates with mortality rates after hospital discharge. JAMA - J Am Med Assoc. 318(3):270–278. https://doi.org/10.1001/jama.2017.8444

    Article  Google Scholar 

  3. Ryan J, Kang S, Dolacky S, Ingrassia J, Ganeshan R (2013) Change in readmissions and follow-up visits as part of a heart failure readmission quality improvement initiative. Am J Med 126(11):989–994. https://doi.org/10.1016/j.amjmed.2013.06.027

    Article  PubMed  Google Scholar 

  4. Zuckerman RB, Sheingold SH, Orav EJ, Ruhter J, Epstein AM (2016) Readmissions, observation, and the hospital readmissions reduction program. N Engl J Med 374(16):1543–1551. https://doi.org/10.1056/NEJMsa1513024

    Article  CAS  PubMed  Google Scholar 

  5. Heidenreich PA, Albert NM, Allen LA, Bluemke DA, Butler J, Fonarow GC, Ikonomidis JS, Khavjou O, Konstam MA, Maddox TM, Nichol G, Pham M, Piña IL, Trogdon JG, American Heart Association Advocacy Coordinating Committee, Council on Arteriosclerosis, Thrombosis and Vascular Biology, Council on Cardiovascular Radiology and Intervention, Council on Clinical Cardiology, Council on Epidemiology and Prevention, Stroke Council (2013) Forecasting the impact of heart failure in the United States: a policy statement from the American Heart Association. Circ Hear Fail 6(3):606–619. https://doi.org/10.1161/HHF.0b013e318291329a

    Article  CAS  Google Scholar 

  6. Center for Health Statistics N (2015) Documentation initial release mortality multiple cause-of-death public use record. 2013. https://www.cdc.gov/nchs/data/dvs/multiple_cause_record_layout_2015.pdf. Accessed 17 August 2017

  7. Gheorghiade M, Vaduganathan M, Fonarow GC, Bonow RO (2013) Rehospitalization for heart failure: problems and perspectives. J Am Coll Cardiol 61(4):391–403. https://doi.org/10.1016/j.jacc.2012.09.038

    Article  PubMed  Google Scholar 

  8. Packer M, Bristow MR, Cohn JN, Colucci WS, Fowler MB, Gilbert EM, Shusterman NH (1996) The effect of carvedilol on morbidity and mortality in patients with chronic heart failure. N Engl J Med 334(21):1349–1355. https://doi.org/10.1056/NEJM199605233342101

    Article  CAS  PubMed  Google Scholar 

  9. Poole-Wilson PA, Swedberg K, Cleland JG et al (2003) Comparison of carvedilol and metoprolol on clinical outcomes in patients with chronic heart failure in the Carvedilol Or Metoprolol European Trial (COMET): randomised controlled trial. Lancet 362(9377):7–13. https://doi.org/10.1016/S0140-6736(03)13800-7

    Article  CAS  PubMed  Google Scholar 

  10. Hjalmarson A, Goldstein S, Fagerberg B et al. (1999) Effect of metoprolol CR/XL in chronic heart failure: Metoprolol CR/XL Randomised Intervention Trial in Congestive Heart Failure (MERIT-HF). Lancet 353(9169):2001–2007. https://doi.org/10.1016/S0140-6736(99)04440-2

    Article  Google Scholar 

  11. Morisco C, Condorelli M, Crepaldi G, Rizzon P, Zardini P, Villa G, Argenziano L, Trimarco B (1997) Lisinopril in the treatment of congestive heart failure in elderly patients: comparison versus captopril. Cardiovasc Drugs Ther 11(1):63–69. https://doi.org/10.1023/A:1007704024393

    Article  CAS  PubMed  Google Scholar 

  12. Investigators* TS (1991) Effect of Enalapril on survival in patients with reduced left ventricular ejection fractions and congestive heart failure. N Engl J Med 325(5):293–302. https://doi.org/10.1056/NEJM199108013250501

    Article  Google Scholar 

  13. Pfeffer MA, Braunwald E, Moyé LA, Basta L, Brown EJ Jr, Cuddy TE, Davis BR, Geltman EM, Goldman S, Flaker GC, Klein M, Lamas GA, Packer M, Rouleau J, Rouleau JL, Rutherford J, Wertheimer JH, Hawkins CM (1992) Effect of captopril on mortality and morbidity in patients with left ventricular dysfunction after myocardial infarction. N Engl J Med 327(10):669–677. https://doi.org/10.1056/NEJM199209033271001

    Article  CAS  PubMed  Google Scholar 

  14. Group* TCTS (1987) Effects of Enalapril on mortality in severe congestive heart failure. N Engl J Med 316(23):1429–1435. https://doi.org/10.1056/NEJM198706043162301

    Article  Google Scholar 

  15. Pitt B (1999) The effect of spironolactone on morbidity and mortality in patients with severe heart failure. N Engl J Med 341(10):709–717. https://doi.org/10.1056/NEJM199909023411001

    Article  CAS  PubMed  Google Scholar 

  16. Pitt B, Remme W, Zannad F, Neaton J, Martinez F, Roniker B, Bittman R, Hurley S, Kleiman J, Gatlin M, Eplerenone Post-Acute Myocardial Infarction Heart Failure Efficacy and Survival Study Investigators (2003) Eplerenone, a selective aldosterone blocker, in patients with left ventricular dysfunction after myocardial infarction. N Engl J Med 348(14):1309–1321. https://doi.org/10.1056/NEJMoa030207

    Article  CAS  PubMed  Google Scholar 

  17. Yancy CW, Jessup M, Bozkurt B, Butler J, Casey DE Jr, Colvin MM, Drazner MH, Filippatos GS, Fonarow GC, Givertz MM, Hollenberg SM, Lindenfeld JA, Masoudi FA, McBride PE, Peterson PN, Stevenson LW, Westlake C (2017) ACC/AHA/HFSA focused update of the 2013 ACCF/AHA guideline for the management of heart failure: a report of the American College of Cardiology/American Heart Association task force on clinical practice guidelines and the heart failure society of America. Circulation 136(6):e137–e161. https://doi.org/10.1161/CIR.0000000000000509

    Article  PubMed  Google Scholar 

  18. McMurray JJV, Packer M, Desai AS, Gong J, Lefkowitz MP, Rizkala AR, Rouleau JL, Shi VC, Solomon SD, Swedberg K, Zile MR, PARADIGM-HF Investigators and Committees (2014) Angiotensin–neprilysin inhibition versus enalapril in heart failure. N Engl J Med 371(11):993–1004. https://doi.org/10.1056/NEJMoa1409077

    Article  CAS  PubMed  Google Scholar 

  19. Solomon SD, Claggett B, Packer M, Desai A, Zile MR, Swedberg K, Rouleau J, Shi V, Lefkowitz M, McMurray JJV (2016) Efficacy of sacubitril/valsartan relative to a prior decompensation: the PARADIGM-HF trial. JACC Hear Fail 4(10):816–822. https://doi.org/10.1016/j.jchf.2016.05.002

    Article  Google Scholar 

  20. Swedberg K, Komajda M, Böhm M et al (2010) Ivabradine and outcomes in chronic heart failure (SHIFT): a randomised placebo-controlled study. Lancet (London, England) 376(9744):875–885. https://doi.org/10.1016/S0140-6736(10)61198-1

    Article  CAS  Google Scholar 

  21. Pfeffer MA, Claggett B, Assmann SF, Boineau R, Anand IS, Clausell N, Desai AS, Diaz R, Fleg JL, Gordeev I, Heitner JF, Lewis EF, O’Meara E, Rouleau JL, Probstfield JL, Shaburishvili T, Shah SJ, Solomon SD, Sweitzer NK, McKinlay SM, Pitt B (2015) Regional variation in patients and outcomes in the treatment of preserved cardiac function heart failure with an aldosterone antagonist (TOPCAT) trial. Circulation 131(1):34–42. https://doi.org/10.1161/CIRCULATIONAHA.114.013255

    Article  CAS  PubMed  Google Scholar 

  22. Ouwerkerk W, Voors AA, Anker SD, Cleland JG, Dickstein K, Filippatos G, van der Harst P, Hillege HL, Lang CC, ter Maaten JM, Ng LL, Ponikowski P, Samani NJ, van Veldhuisen DJ, Zannad F, Metra M, Zwinderman AH (2017) Determinants and clinical outcome of uptitration of ACE-inhibitors and beta-blockers in patients with heart failure: a prospective European study. Eur Heart J 38(24):1883–1890. https://doi.org/10.1093/eurheartj/ehx026

    Article  CAS  PubMed  Google Scholar 

  23. Komajda M, Cowie MR, Tavazzi L, Ponikowski P, Anker SD, Filippatos GS (2017) Physicians’ guideline adherence is associated with better prognosis in outpatients with heart failure with reduced ejection fraction: the QUALIFY international registry. Eur J Heart Fail 19(11):1414–1423. https://doi.org/10.1002/ejhf.887

    Article  CAS  PubMed  Google Scholar 

  24. Luo N, Ballew NG, O’Brien EC et al (2018) Early impact of guideline publication on angiotensin-receptor neprilysin inhibitor use among patients hospitalized for heart failure. Am Heart J 200:134–140. https://doi.org/10.1016/j.ahj.2018.01.009

    Article  CAS  PubMed  Google Scholar 

  25. Crespo-Leiro MG, Anker SD, Maggioni AP, Coats AJ, Filippatos G, Ruschitzka F, Ferrari R, Piepoli MF, Delgado Jimenez JF, Metra M, Fonseca C, Hradec J, Amir O, Logeart D, Dahlström U, Merkely B, Drozdz J, Goncalvesova E, Hassanein M, Chioncel O, Lainscak M, Seferovic PM, Tousoulis D, Kavoliuniene A, Fruhwald F, Fazlibegovic E, Temizhan A, Gatzov P, Erglis A, Laroche C, Mebazaa A, on behalf of the Heart Failure Association (HFA) of the European Society of Cardiology (ESC) (2016) European Society of Cardiology Heart Failure Long-Term Registry (ESC-HF-LT): 1-year follow-up outcomes and differences across regions. Eur J Heart Fail 18(6):613–625. https://doi.org/10.1002/ejhf.566

    Article  PubMed  Google Scholar 

  26. Bakris GL, Pitt B, Weir MR, Freeman MW, Mayo MR, Garza D, Stasiv Y, Zawadzki R, Berman L, Bushinsky DA, AMETHYST-DN Investigators (2015) Effect of patiromer on serum potassium level in patients with hyperkalemia and diabetic kidney disease the AMETHYST-DN randomized clinical trial. JAMA - J Am Med Assoc 314(2):151–161. https://doi.org/10.1001/jama.2015.7446

    Article  CAS  Google Scholar 

  27. Weir MR, Bakris GL, Bushinsky DA, Mayo MR, Garza D, Stasiv Y, Wittes J, Christ-Schmidt H, Berman L, Pitt B, OPAL-HK Investigators (2015) Patiromer in patients with kidney disease and hyperkalemia receiving RAAS inhibitors. N Engl J Med 372(3):211–221. https://doi.org/10.1056/NEJMoa1410853

    Article  CAS  PubMed  Google Scholar 

  28. Fitzgerald AA, Powers JD, Ho PM, Maddox TM, Peterson PN, Allen LA, Masoudi FA, Magid DJ, Havranek EP (2011) Impact of medication nonadherence on hospitalizations and mortality in heart failure. J Card Fail 17(8):664–669. https://doi.org/10.1016/j.cardfail.2011.04.011

    Article  PubMed  Google Scholar 

  29. Gattis WA, O’Connor CM, Gallup DS, Hasselblad V, Gheorghiade M (2004) Predischarge initiation of carvedilol in patients hospitalized for decompensated heart failure: results of the initiation management predischarge: process for assessment of carvedilol therapy in heart failure (IMPACT-HF) trial. J Am Coll Cardiol 43(9):1534–1541. https://doi.org/10.1016/j.jacc.2003.12.040

    Article  CAS  PubMed  Google Scholar 

  30. Smaha LA, American Heart Association (2004) The American Heart Association get with the guidelines program. Am Heart J 148(5 SUPPL):S46–S48. https://doi.org/10.1016/j.ahj.2004.09.015

    Article  PubMed  Google Scholar 

  31. Ziaeian B, Araujo KLB, Van Ness PH, Horwitz LI (2012) Medication reconciliation accuracy and patient understanding of intended medication changes on hospital discharge. J Gen Intern Med 27(11):1513–1520. https://doi.org/10.1007/s11606-012-2168-4

    Article  PubMed  PubMed Central  Google Scholar 

  32. Sueta CA, Rodgers JE, Chang PP, Zhou L, Thudium EM, Kucharska-Newton AM, Stearns SC (2015) Medication adherence based on part D claims for patients with heart failure after hospitalization (from the atherosclerosis risk in communities study). Am J Cardiol 116(3):413–419. https://doi.org/10.1016/j.amjcard.2015.04.058

    Article  PubMed  PubMed Central  Google Scholar 

  33. Dovancescu S, Pellicori P, Mabote T, Torabi A, Clark AL, Cleland JGF (2017) The effects of short-term omission of daily medication on the pathophysiology of heart failure. Eur J Heart Fail 19(5):643–649. https://doi.org/10.1002/ejhf.748

    Article  PubMed  Google Scholar 

  34. Ruppar TM, Cooper PS, Mehr DR, Delgado JM, Dunbar-Jacob JM (2016) Medication adherence interventions improve heart failure mortality and readmission rates: systematic review and meta-analysis of controlled trials. J Am Heart Assoc 5(6):1–19. https://doi.org/10.1161/JAHA.115.002606

    Article  Google Scholar 

  35. Conn VS, Ruppar TM, Chan KC, Dunbar-Jacob J, Pepper GA, De Geest S (2015) Packaging interventions to increase medication adherence: systematic review and meta-analysis. Curr Med Res Opin 31(1):145–160. https://doi.org/10.1185/03007995.2014.978939

    Article  PubMed  Google Scholar 

  36. Hale TM, Jethwani K, Kandola MS, Saldana F, Kvedar JC (2016) A remote medication monitoring system for chronic heart failure patients to reduce readmissions: a two-arm randomized pilot study. J Med Internet Res 18(5):1–14. https://doi.org/10.2196/jmir.5256

    Article  Google Scholar 

  37. Palmer MJ, Barnard S, Perel P, Free C (2018) Mobile phone-based interventions for improving adherence to medication prescribed for the primary prevention of cardiovascular disease in adults. Cochrane Database Syst Rev (6):CD012675. https://doi.org/10.1002/14651858.CD012675.pub2

  38. Asch DA, Troxel AB, Stewart WF, Sequist TD, Jones JB, Hirsch AMG, Hoffer K, Zhu J, Wang W, Hodlofski A, Frasch AB, Weiner MG, Finnerty DD, Rosenthal MB, Gangemi K, Volpp KG (2015) Effect of financial incentives to physicians, patients, or both on lipid levels: a randomized clinical trial. JAMA - J Am Med Assoc 314(18):1926–1935. https://doi.org/10.1001/jama.2015.14850

    Article  CAS  Google Scholar 

  39. Volpp KG, Troxel AB, Mehta SJ, Norton L, Zhu J, Lim R, Wang W, Marcus N, Terwiesch C, Caldarella K, Levin T, Relish M, Negin N, Smith-McLallen A, Snyder R, Spettell CM, Drachman B, Kolansky D, Asch DA (2017) Effect of electronic reminders, financial incentives, and social support on outcomes after myocardial infarction the heartstrong randomized clinical trial. JAMA Intern Med 177(8):1093–1101. https://doi.org/10.1001/jamainternmed.2017.2449

    Article  PubMed  PubMed Central  Google Scholar 

  40. Picano E, Gargani L, Gheorghiade M (2010) Why, when, and how to assess pulmonary congestion in heart failure: pathophysiological, clinical, and methodological implications. Heart Fail Rev 15(1):63–72. https://doi.org/10.1007/s10741-009-9148-8

    Article  PubMed  Google Scholar 

  41. Melenovsky V, Andersen MJ, Andress K, Reddy YN, Borlaug BA (2015) Lung congestion in chronic heart failure: Haemodynamic, clinical, and prognostic implications. Eur J Heart Fail 17(11):1161–1171. https://doi.org/10.1002/ejhf.417

    Article  CAS  PubMed  Google Scholar 

  42. Böhm M, Drexler H, Oswald H, Rybak K, Bosch R, Butter C, Klein G, Gerritse B, Monteiro J, Israel C, Bimmel D, Käab S, Huegl B, Brachmann J, OptiLink HF Study Investigators (2016) Fluid status telemedicine alerts for heart failure: a randomized controlled trial. Eur Heart J 37(41):3154–3163. https://doi.org/10.1093/eurheartj/ehw099

    Article  PubMed  Google Scholar 

  43. Bourge RC, Abraham WT, Adamson PB, Aaron MF, Aranda JM Jr, Magalski A, Zile MR, Smith AL, Smart FW, O'Shaughnessy MA, Jessup ML, Sparks B, Naftel DL, Stevenson LW, COMPASS-HF Study Group (2008) Randomized controlled trial of an implantable continuous hemodynamic monitor in patients with advanced heart failure. The COMPASS-HF study. J Am Coll Cardiol 51(11):1073–1079. https://doi.org/10.1016/j.jacc.2007.10.061

    Article  PubMed  Google Scholar 

  44. Heywood JT, Jermyn R, Shavelle D, Abraham WT, Bhimaraj A, Bhatt K, Sheikh F, Eichorn E, Lamba S, Bharmi R, Agarwal R, Kumar C, Stevenson LW (2017) Impact of practice-based management of pulmonary artery pressures in 2000 patients implanted with the CardioMEMS sensor. Circulation 135(16):1509–1517. https://doi.org/10.1161/CIRCULATIONAHA.116.026184

    Article  PubMed  Google Scholar 

  45. Coiro S, Rossignol P, Ambrosio G, Carluccio E, Alunni G, Murrone A, Tritto I, Zannad F, Girerd N (2015) Prognostic value of residual pulmonary congestion at discharge assessed by lung ultrasound imaging in heart failure. Eur J Heart Fail 17(11):1172–1181. https://doi.org/10.1002/ejhf.344

    Article  PubMed  Google Scholar 

  46. Kociol RD, Horton JR, Fonarow GC, Reyes EM, Shaw LK, O’Connor CM, Felker GM, Hernandez AF (2011) Admission, discharge, or change in B-type natriuretic peptide and long-term outcomes: data from organized program to initiate lifesaving treatment in hospitalized patients with heart failure (OPTIMIZE-HF) linked to Medicare claims. Circ Hear Fail 4(5):628–636. https://doi.org/10.1161/CIRCHEARTFAILURE.111.962290

    Article  CAS  Google Scholar 

  47. Hamatani Y, Nagai T, Shiraishi Y, Kohsaka S, Nakai M, Nishimura K, Kohno T, Nagatomo Y, Asaumi Y, Goda A, Mizuno A, Yasuda S, Ogawa H, Yoshikawa T, Anzai T, Investigators for the WET-NaDEF Collaboration Project (2018) Long-term prognostic significance of plasma B-type natriuretic peptide level in patients with acute heart failure with reduced, mid-range, and preserved ejection fractions. Am J Cardiol 121(6):731–738. https://doi.org/10.1016/j.amjcard.2017.12.012

    Article  CAS  PubMed  Google Scholar 

  48. Stienen S, Salah K, Moons AH, Bakx AL, van Pol P, Kortz RAM, Ferreira JP, Marques I, Schroeder-Tanka JM, Keijer JT, Bayés-Genis A, Tijssen JGP, Pinto YM, Kok WE (2018) NT-proBNP (N-terminal pro-B-type natriuretic peptide)-guided therapy in acute decompensated heart failure. Circulation 137(16):1671–1683. https://doi.org/10.1161/CIRCULATIONAHA.117.029882

    Article  CAS  PubMed  Google Scholar 

  49. McQuade CN, Mizus M, Wald JW, Goldberg L, Jessup M, Umscheid CA (2017) Brain-type natriuretic peptide and amino-terminal pro-brain-type natriuretic peptide discharge thresholds for acute decompensated heart failure: a systematic review. Ann Intern Med 166(3):180–190. https://doi.org/10.7326/M16-1468

    Article  PubMed  Google Scholar 

  50. Holly C (2011) Structured telephone support or telemonitoring programmes for patients with chronic heart failure. Inglis SC, ed. Int J Evid Based Healthc 9(3):274–275. https://doi.org/10.1111/j.1744-1609.2011.00230.x

    Article  Google Scholar 

  51. Blum K, Gottlieb SS (2014) The effect of a randomized trial of home telemonitoring on medical costs, 30-day readmissions, mortality, and health-related quality of life in a cohort of community-dwelling heart failure patients. J Card Fail 20(7):513–521. https://doi.org/10.1016/j.cardfail.2014.04.016

    Article  PubMed  Google Scholar 

  52. Chaudhry SI, Mattera JA, Curtis JP, Spertus JA, Herrin J, Lin Z, Phillips CO, Hodshon BV, Cooper LS, Krumholz HM (2010) Telemonitoring in patients with heart failure. N Engl J Med 363(24):2301–2309. https://doi.org/10.1056/NEJMoa1010029

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  53. Ong MK, Romano PS, Edgington S, Aronow HU, Auerbach AD, Black JT, de Marco T, Escarce JJ, Evangelista LS, Hanna B, Ganiats TG, Greenberg BH, Greenfield S, Kaplan SH, Kimchi A, Liu H, Lombardo D, Mangione CM, Sadeghi B, Sadeghi B, Sarrafzadeh M, Tong K, Fonarow GC, for the Better Effectiveness After Transition–Heart Failure (BEAT-HF) Research Group (2016) Effectiveness of remote patient monitoring after discharge of hospitalized patients with heart failure: the better effectiveness after transition-heart failure (BEAT-HF) randomized clinical trial. JAMA Intern Med 176(3):310–318. https://doi.org/10.1001/jamainternmed.2015.7712

    Article  PubMed  PubMed Central  Google Scholar 

  54. Boriani G, Da Costa A, Quesada A et al (2017) Effects of remote monitoring on clinical outcomes and use of healthcare resources in heart failure patients with biventricular defibrillators: results of the MORE-CARE multicentre randomized controlled trial. Eur J Heart Fail 19(3):416–425. https://doi.org/10.1002/ejhf.626

    Article  PubMed  Google Scholar 

  55. Metra M, Carubelli V Postdischarge outcomes of patients hospitalized for heart failure - Medicographia. Medicographia. https://www.medicographia.com/2015/10/postdischarge-outcomes-of-patients-hospitalized-for-heart-failure/. Published 2015. Accessed 13 Sept 2018

  56. Bradley E, Curry L, Horwitz L, Sipsma H (2013) Hospital strategies associated with 30-day readmission rates for patients with heart failure. Qual Outcomes 6(4). http://circoutcomes.ahajournals.org/content/6/4/444.long. Accessed 24 August 2017

  57. Salim Al-Damluji M, Dzara K, Hodshon B, et al (2015) Association of discharge summary quality with readmission risk for patients hospitalized with heart failure exacerbation. Circ Cardiovasc Qual Outcomes 8(1). http://circoutcomes.ahajournals.org/content/8/1/109.long. Accessed 24 August 2017

  58. Grafft CA, McDonald FS, Ruud KL, Liesinger JT, Johnson MG, Naessens JM (2010) Effect of hospital followup appointment on clinical event outcomes and mortality. Arch Intern Med 170(11):955–960. https://doi.org/10.1001/archinternmed.2010.105

    Article  PubMed  Google Scholar 

  59. Phillips CO, Wright SM, Kern DE, Singa RM, Shepperd S, Rubin HR (2004) Comprehensive discharge planning with postdischarge support for older patients with congestive heart failure. JAMA 291(11):1358–1367. https://doi.org/10.1001/jama.291.11.1358

    Article  CAS  PubMed  Google Scholar 

  60. McAlister FA, Stewart S, Ferrua S, McMurray JJJV (2004) Multidisciplinary strategies for the management of heart failure patients at high risk for admission: a systematic review of randomized trials. J Am Coll Cardiol 44(4):810–819. https://doi.org/10.1016/j.jacc.2004.05.055

    Article  PubMed  Google Scholar 

  61. Riegel B, Masterson Creber R, Hill J, Chittams J, Hoke L (2016) Clemmer Steinbright Professor E. Effectiveness of motivational interviewing in decreasing hospital readmission in adults with heart failure and multimorbidity. Clin Nurs Res 25(4):362–377. https://doi.org/10.1177/1054773815623252

    Article  PubMed  PubMed Central  Google Scholar 

  62. Brandon AF, Schuessler JB, Ellison KJ, Lazenby RB (2009) The effects of an advanced practice nurse led telephone intervention on outcomes of patients with heart failure. Appl Nurs Res 22(4):e1–e7. https://doi.org/10.1016/j.apnr.2009.02.003

    Article  PubMed  Google Scholar 

  63. STROMBERG A, Mårtensson J, Fridlund B, Levin L-Å, Karlsson J-E, Dahlström U (2003) Nurse-led heart failure clinics improve survival and self-care behaviour in patients with heart failure. Results from a prospective, randomised trial. Eur Heart J 24(11):1014–1023. https://doi.org/10.1016/S0195-668X(03)00112-X

    Article  CAS  PubMed  Google Scholar 

  64. Krumholz HM, Amatruda J, Smith GL, Mattera JA, Roumanis SA, Radford MJ, Crombie P, Vaccarino V (2002) Randomized trial of an education and support intervention to prevent readmission of patients with heart failure. J Am Coll Cardiol 39(1):83–89. https://doi.org/10.1016/S0735-1097(01)01699-0

    Article  PubMed  Google Scholar 

  65. Donzé JD, Williams MV, Robinson EJ, Zimlichman E, Aujesky D, Vasilevskis EE, Kripalani S, Metlay JP, Wallington T, Fletcher GS, Auerbach AD, Schnipper JL (2016) International validity of the HOSPITAL score to predict 30-day potentially avoidable hospital readmissions. JAMA Intern Med 176(4):496–502. https://doi.org/10.1001/jamainternmed.2015.8462

    Article  PubMed  PubMed Central  Google Scholar 

  66. Damery S, Combes G (2017) Evaluating the predictive strength of the LACE index in identifying patients at high risk of hospital readmission following an inpatient episode: a retrospective cohort study. BMJ Open 7(7):e016921. https://doi.org/10.1136/bmjopen-2017-016921

    Article  PubMed  PubMed Central  Google Scholar 

  67. Hakim MA, Garden FL, Jennings MD, Dobler CC (2018) Performance of the LACE index to predict 30-day hospital readmissions in patients with chronic obstructive pulmonary disease. Clin Epidemiol 10:51–59. https://doi.org/10.2147/CLEP.S149574

    Article  PubMed  Google Scholar 

  68. Robinson R, Hudali T (2017) The HOSPITAL score and LACE index as predictors of 30 day readmission in a retrospective study at a university-affiliated community hospital. PeerJ 5:e3137. https://doi.org/10.7717/peerj.3137

    Article  PubMed  PubMed Central  Google Scholar 

  69. Kansagara D, Englander H, Salanitro A, Kagen D, Theobald C, Freeman M, Kripalani S (2011) Risk prediction models for hospital readmission. JAMA 306(15):1688–1698. https://doi.org/10.1001/jama.2011.1515

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  70. Saito M, Negishi K, Marwick TH (2016) Meta-analysis of risks for short-term readmission in patients with heart failure. Am J Cardiol 117(4):626–632. https://doi.org/10.1016/j.amjcard.2015.11.048

    Article  PubMed  Google Scholar 

  71. Huynh QL, Negishi K, Blizzard L, Sanderson K, Venn AJ, Marwick TH (2016) Predictive score for 30-day readmission or death in heart failure. JAMA Cardiol 1(3):362–364. https://doi.org/10.1001/jamacardio.2016.0220

    Article  PubMed  Google Scholar 

  72. Van Walraven C, Jennings A, Forster AJ (2012) A meta-analysis of hospital 30-day avoidable readmission rates. J Eval Clin Pract 18(6):1211–1218. https://doi.org/10.1111/j.1365-2753.2011.01773.x

    Article  PubMed  Google Scholar 

  73. Nuckols TK, Keeler E, Morton S, Anderson L, Doyle BJ, Pevnick J, Booth M, Shanman R, Arifkhanova A, Shekelle P (2017) Economic evaluation of quality improvement interventions designed to prevent hospital readmission. JAMA Intern Med 177(7):975–985. https://doi.org/10.1001/jamainternmed.2017.1136

    Article  PubMed  PubMed Central  Google Scholar 

  74. Ziaeian B, Fonarow GC (2016) The prevention of hospital readmissions in heart failure. Prog Cardiovasc Dis 58(4):379–385. https://doi.org/10.1016/j.pcad.2015.09.004

    Article  PubMed  Google Scholar 

  75. Butler J, Kalogeropoulos A (2012) Hospital strategies to reduce heart failure readmissions: where is the evidence? J Am Coll Cardiol 60(7):615–617. https://doi.org/10.1016/j.jacc.2012.03.066

    Article  PubMed  Google Scholar 

Download references

Author information

Authors and Affiliations

  1. University of Connecticut Health Center, 263 Farmington Avenue, Farmington, CT, 06032, USA

    David Goldgrab, Kathir Balakumaran, Min Jung Kim & Sara R. Tabtabai

Authors
  1. David Goldgrab
    View author publications

    You can also search for this author in PubMed Google Scholar

  2. Kathir Balakumaran
    View author publications

    You can also search for this author in PubMed Google Scholar

  3. Min Jung Kim
    View author publications

    You can also search for this author in PubMed Google Scholar

  4. Sara R. Tabtabai
    View author publications

    You can also search for this author in PubMed Google Scholar

Corresponding author

Correspondence to Sara R. Tabtabai.

Ethics declarations

Conflict of interest

The authors declare that they have no conflict of interest.

Rights and permissions

Reprints and permissions

About this article

Check for updates. Verify currency and authenticity via CrossMark

Cite this article

Goldgrab, D., Balakumaran, K., Kim, M.J. et al. Updates in heart failure 30-day readmission prevention. Heart Fail Rev 24, 177–187 (2019). https://doi.org/10.1007/s10741-018-9754-4

Download citation

  • Published:

  • Issue Date:

  • DOI: https://doi.org/10.1007/s10741-018-9754-4

Keywords

Search

Navigation